Vectura Group Share Price (VEC)

143.20 -1.50 (-1.04%) delayed: 6:54PM GMT
Bid price 143.20 Open price 144.90
Ask price 143.40 Prev close 143.20
High price 144.90 Spread 0.14%
Low price 143.00 Volume 1,266,844

Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.

Vectura Group Share Price Chart

Advanced Charts >>

Register now for FREE Vectura Group share price charts

Vectura Group Share Price Information

Name Vectura Group Epic VEC
Sector Pharmaceuticals & Biotechnology ISIN GB00B01D1K48
Activites Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. Index FTSE 250

Vectura Group Key Numbers

Latest Share Price (p) 143.20 Net Gearing (%) -17.92
Market Capitalisation (£m) 981.03 Gross Gearing (%) 17.01
Shares in issue (m) 677.98 Debt Ratio 8.28
P/E Ratio 120.58 Debt-to-Equity Ratio 0.44
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.21
Dividend Yield (%) 0.00 Price to book value 4.14
Dividend cover (x) 0.00 ROCE (%) -0.73
Earning per share (p) 1.20 EPS Growth (%) 33.33
52 week high / low 179.00 / 122.80 DPS Growth (%) n/a

Vectura Group Director Deals

Dec.Date Type Director Pos No. of Shares
09/02/2017 BUY Andrew Derodra FD 111
03/10/2016 BUY Susan Foden NED 6,500
30/09/2016 BUY Andrew Derodra FD 30,000
28/09/2016 EXR Dr Trevor Phillips ED 510,952
28/09/2016 SEXR Dr Trevor Phillips ED 240,841

More Vectura Group Director Deals >>

Vectura Group Company News

07:29 16/02/2017

Vectura achieves £9m royalty cap

Vectura Group says it has achieved the £9m calendar year royalty cap on net sales of GSK's Ellipta products in 2016. This was a year earlier than previously guided, and was based on the continued strong performance of Ellipta products and the group's subsequent receipt of its royalty statement...

07:03 16/02/2017

FLASH: Vectura achieves £9m royalty cap

Story provided by

07:00 16/02/2017

Vectura achieves £9 million royalty cap

RNS Number : 0193X Vectura Group plc 16 February 2017   Vectura Group plc Vectura achieves £9 million royalty cap from GSK Ellipta ® products Chippenham, UK, 16 February 2017:  Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading inhaled airways...

More Vectura Group Company News >>

Register now for FREE Vectura Group company news

Vectura Group Share Price Discussions

5 months ago


Powered by IST's

Register now for FREE Vectura Group share price discussions